AR007195A1 - Forma farmaceutica de dosificacion, proceso para prepararla y uso de la misma para la preparacion de un medicamento para el tratamiento de infecciones virales - Google Patents

Forma farmaceutica de dosificacion, proceso para prepararla y uso de la misma para la preparacion de un medicamento para el tratamiento de infecciones virales

Info

Publication number
AR007195A1
AR007195A1 ARP970102113A ARP970102113A AR007195A1 AR 007195 A1 AR007195 A1 AR 007195A1 AR P970102113 A ARP970102113 A AR P970102113A AR P970102113 A ARP970102113 A AR P970102113A AR 007195 A1 AR007195 A1 AR 007195A1
Authority
AR
Argentina
Prior art keywords
mixture
prepare
particles
dosage
drug
Prior art date
Application number
ARP970102113A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26142825&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR007195(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR007195A1 publication Critical patent/AR007195A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
ARP970102113A 1996-05-20 1997-05-19 Forma farmaceutica de dosificacion, proceso para prepararla y uso de la misma para la preparacion de un medicamento para el tratamiento de infecciones virales AR007195A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201430 1996-05-20
EP97200698 1997-03-07

Publications (1)

Publication Number Publication Date
AR007195A1 true AR007195A1 (es) 1999-10-13

Family

ID=26142825

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102113A AR007195A1 (es) 1996-05-20 1997-05-19 Forma farmaceutica de dosificacion, proceso para prepararla y uso de la misma para la preparacion de un medicamento para el tratamiento de infecciones virales

Country Status (34)

Country Link
US (4) US6509038B2 (fr)
EP (1) EP0904060B1 (fr)
JP (1) JP3391801B2 (fr)
KR (1) KR19990044257A (fr)
CN (1) CN1165291C (fr)
AR (1) AR007195A1 (fr)
AT (1) ATE255883T1 (fr)
AU (1) AU722101B2 (fr)
BG (1) BG64368B1 (fr)
BR (1) BR9706897B1 (fr)
CA (1) CA2240161C (fr)
CY (1) CY2434B1 (fr)
CZ (1) CZ293841B6 (fr)
DE (1) DE69726729T2 (fr)
DK (1) DK0904060T3 (fr)
EA (1) EA001219B1 (fr)
EE (1) EE03902B1 (fr)
ES (1) ES2212810T3 (fr)
HK (1) HK1018002A1 (fr)
HR (1) HRP970270B1 (fr)
HU (1) HU227745B1 (fr)
ID (1) ID16926A (fr)
IL (1) IL124935A (fr)
MX (1) MX9805418A (fr)
MY (1) MY123827A (fr)
NO (1) NO320495B1 (fr)
NZ (1) NZ330739A (fr)
PL (1) PL188566B1 (fr)
PT (1) PT904060E (fr)
SI (1) SI0904060T1 (fr)
SK (1) SK284145B6 (fr)
TR (1) TR199801225T2 (fr)
TW (1) TW460282B (fr)
WO (1) WO1997044014A1 (fr)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
JP3696087B2 (ja) * 1997-12-31 2005-09-14 チョンワエ ファーマ コーポレーション イトラコナゾール（ｉｔｒａｃｏｎａｚｏｌｅ）経口用製剤及びその製造方法
KR100288890B1 (ko) * 1997-12-31 2001-05-02 최현식 이트라코나졸 경구용 제제 및 그의 제조방법
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
ATE307808T1 (de) 1999-03-24 2005-11-15 Scherer Technologies Inc R P Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
EP1175205B1 (fr) 1999-11-12 2006-06-14 Abbott Laboratories Dispersion solide comrpenant ritonavir, fenofibrate ou griseofulvin
WO2001047492A1 (fr) * 1999-12-23 2001-07-05 F H Faulding & Co Limited Compositions pharmaceutiques ameliorees pour medicaments peu solubles
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
BR0111868A (pt) * 2000-06-22 2003-07-01 Novartis Ag Composições farmacêuticas
DE10038571A1 (de) * 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
ES2275866T3 (es) 2001-02-14 2007-06-16 Tibotec Pharmaceuticals Ltd. 2-(aminosustituido)-benzotiazol-sulfonamidas de amplio esprecto inhibidoras de la proteasa de vih.
AP1544A (en) 2001-04-09 2006-01-12 Tibotec Pharm Ltd Broadspectrum 2- (substituted-amino) -benzoxazole sulfonamide HIV protease inhibitors.
EA009590B1 (ru) 2001-05-11 2008-02-28 Тиботек Фармасьютикалз Лтд. 2-аминобензоксазолсульфонамидные ингибиторы вич-протеазы широкого спектра
WO2002100407A1 (fr) * 2001-06-12 2002-12-19 Smartrix Technologies Inc. Granules d'itraconazole: formulations pharmaceutiques pour administration orale et procede de preparation de ces dernieres
ATE444060T1 (de) 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
US7163700B2 (en) * 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
UA79248C2 (en) 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
CA2363376A1 (fr) * 2001-11-16 2003-05-16 Bernard Charles Sherman Compositions pharmaceutiques solides, comprenant de l'itraconazole, destinees a l'administration orale
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
JP4578101B2 (ja) 2001-12-21 2010-11-10 テイボテク・フアーマシユーチカルズ・リミテツド 幅広いスペクトルのｈｉｖプロテアーゼ阻害剤である複素環置換フェニル含有スルホンアミド
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
KR100717098B1 (ko) * 2002-02-28 2007-05-10 니뽄 다바코 산교 가부시키가이샤 에스테르 화합물 및 그 의약 용도
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
ATE371652T1 (de) 2002-05-17 2007-09-15 Tibotec Pharm Ltd Substituierte benzisoxazolsulfonamide mit breitbändiger hiv-protease hemmender wirkung
WO2004004683A1 (fr) * 2002-07-04 2004-01-15 Janssen Pharmaceutica N.V. Dispersions solides comprenant deux matrices polymeriques distinctes
JP4681296B2 (ja) 2002-08-14 2011-05-11 テイボテク・フアーマシユーチカルズ・リミテツド スペクトルの広い置換オキシインドールスルホンアミドｈｉｖプロテアーゼ阻害剤
EP2422772A3 (fr) * 2002-09-20 2012-04-18 Alpharma, Inc. Séquestration de sous-unité et compositions et procédés associés
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
DK1438961T4 (da) * 2003-01-14 2014-11-17 Acino Pharma Ag Bioækvivalent sammensætning af itraconazol dispergeret i en hydrofil polymer
JP4783278B2 (ja) * 2003-02-03 2011-09-28 ノバルティス アーゲー 医薬製剤
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
WO2005011702A1 (fr) * 2003-07-17 2005-02-10 Tibotec Pharmaceuticals Ltd. Procede de preparation de particules contenant un agent antiviral
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP1669345A4 (fr) * 2003-08-29 2008-02-20 Japan Tobacco Inc Derive d'ester et utilisation medicale de celui-ci
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
AU2004269930B2 (en) 2003-09-11 2011-08-04 Tibotec Pharmaceuticals Ltd. Entry inhibitors of the HIV virus
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
CA2558027A1 (fr) * 2004-03-03 2005-09-15 Spherics, Inc. Systeme d'administration de medicaments polymeres pour des medicaments hydrophobes
AR048650A1 (es) 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
JP5073480B2 (ja) 2004-05-07 2012-11-14 セコイア、ファーマシューティカルズ、インコーポレイテッド 耐性防止レトロウイルスプロテアーゼ阻害薬
MXPA06013315A (es) 2004-05-17 2007-02-02 Tibotec Pharm Ltd 1,5-dihidro-pirido[3,2-b]indol-2-onas 4-sustituidas.
EP1758911A1 (fr) 2004-05-17 2007-03-07 Tibotec Pharmaceuticals Ltd. 1-heterocyclyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones
ATE481403T1 (de) 2004-05-17 2010-10-15 Tibotec Pharm Ltd Substituierte 1-phenyl-1,5-dihydro-pyridoä3,2- büindol-2-on-derivate verwendbar als pharmazeutische antiinfektiva
WO2005117834A1 (fr) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Dispersions solides d'un compose medicamenteux basique et d'un polymere renfermant des groupes acides
KR20050119397A (ko) * 2004-06-16 2005-12-21 보람제약주식회사 고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
KR100708974B1 (ko) * 2004-07-19 2007-04-18 주식회사종근당 수용성 수지를 이용한 이트라코나졸 고체분산체
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
MX2007004973A (es) * 2004-10-25 2007-06-14 Japan Tobacco Inc Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion.
CA2598204C (fr) 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Composition de petites particules medicamenteuses chauffee et stabilisee
KR101238525B1 (ko) * 2004-12-31 2013-02-28 레디 유에스 테라퓨틱스 인코포레이티드 Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
US20090028938A1 (en) * 2005-08-08 2009-01-29 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
CA2618255C (fr) 2005-08-08 2015-05-26 Abbott Gmbh & Co. Kg Compositions d'itraconazole presentant une biodisponibilite amelioree
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
CA2642761A1 (fr) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions et methodes pour l'induction et la conservation d'un sommeil de qualite
CN101415708A (zh) 2006-04-03 2009-04-22 泰博特克药品有限公司 抑制HIV的3,4-二氢-咪唑并[4,5-b]吡啶-5-酮
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
HUE032156T2 (en) 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
KR20090027734A (ko) * 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법
WO2008063301A2 (fr) * 2006-10-11 2008-05-29 Alpharma, Inc. Compositions pharmaceutiques
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
CA2697099C (fr) * 2007-08-21 2018-02-20 Board Of Regents, The University Of Texas System Melange thermocinetique pour des applications pharmaceutiques
US8821924B2 (en) 2007-09-14 2014-09-02 Wockhardt Ltd. Rhein or diacerein compositions
CA2709236A1 (fr) 2007-09-27 2009-04-02 Wockhardt Research Centre Compositions pharmaceutiques de rheine ou de diacereine
US20090130160A1 (en) * 2007-11-21 2009-05-21 Fiber Innovation Technology, Inc. Fiber for wound dressing
BRPI0819883A2 (pt) 2007-11-28 2017-05-23 Sequoia Pharmaceuticals Inc composições e métodos para inibir citocromo p450 2d6
CA2709905A1 (fr) * 2007-12-17 2009-06-25 Alfred Liang Composition d'oxycodone a l'epreuve d'un usage abusif
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2249808A2 (fr) * 2008-01-11 2010-11-17 Cipla Limited Forme posologique pharmaceutique solide
CA2716348C (fr) 2008-02-21 2017-04-04 Sequoia Pharmaceuticals, Inc. Diamides inhibiteurs du cytochrome p450
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
JP5607550B2 (ja) 2008-03-11 2014-10-15 ディポメド，インコーポレイティド 非オピオイド鎮痛剤及びオピオイド鎮痛剤の組合せを含む胃保持性持続放出剤形
MX2010011295A (es) * 2008-04-15 2010-11-12 Schering Corp Composiciones farmaceuticas orales en una dispersion solida que comprenden preferiblemente posaconazol y acetato-succinato de hidroxipropilmetilcelulosa.
EA200900145A1 (ru) * 2008-12-31 2010-02-26 Открытое Акционерное Общество "Верофарм" Противогрибковое средство для вагинального применения
CN101780046B (zh) * 2009-01-16 2011-09-21 北京化工大学 一种伊曲康唑复合粉体及其制备方法
US10071059B2 (en) 2009-12-18 2018-09-11 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
BR112013008737A2 (pt) * 2010-10-14 2015-09-01 Abbott Gmbh & Co Kg Formulação de dispersão sólida de curcuminóide
CN102068416A (zh) * 2010-12-30 2011-05-25 安徽先求药业有限公司 一种含有伊曲康唑的口服固体制剂及其制备方法
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
EP2744481A4 (fr) * 2011-08-16 2015-07-01 Merck Sharp & Dohme Utilisation de matrice inorganique et de combinaisons de polymères organiques pour la préparation de dispersions amorphes stables
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
WO2013037396A1 (fr) * 2011-09-12 2013-03-21 Bioneer A/S Solution de polymère dans un principe actif pour forme posologique solide
CA2850022C (fr) 2011-09-27 2018-05-01 Dr. Reddy's Laboratories, Ltd. Derives de 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine utiles comme inhibiteurs de la cholesteryl ester-transfer proteine (cetp) dans le traitement de l'atherosc lerose
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (fr) 2012-04-13 2017-10-18 King Saud University Procédé de préparation d'une dispersion solide, dispersion solide ainsi obtenue et son utilisation
CA2876909C (fr) 2012-06-21 2022-08-16 Mayne Pharma International Pty. Ltd. Compositions et formes galeniques d'itraconazole et leurs procedes d'utilisation
WO2014014752A1 (fr) * 2012-07-17 2014-01-23 Dow Global Technologies Llc Dispersion solide comprenant une hydroxyalkyl méthylcellulose fortement substituée
RU2015123632A (ru) 2012-11-19 2017-01-10 Др. Редди'С Лабораторис Лтд. Фармацевтические композиции ингибиторов сетр
MY192032A (en) 2013-01-22 2022-07-24 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
JP6546179B2 (ja) 2014-01-16 2019-07-17 ダウ グローバル テクノロジーズ エルエルシー ３ｄ印刷用支持材料
US10201933B2 (en) * 2015-06-09 2019-02-12 Dow Global Technologies Llc Support materials for 3D printing
EP3454847A4 (fr) * 2016-05-09 2019-12-18 Dispersol Technologies, LLC Formulations de médicaments améliorées
WO2019043427A1 (fr) 2017-09-01 2019-03-07 Jordan Sweden Medical And Sterilization Company Formes posologiques à auto-dispersion rapide de déférasirox
CN109172532A (zh) * 2018-10-24 2019-01-11 北京哈三联科技有限责任公司 一种伊曲康唑分散片及其制备方法和应用
US20220304936A1 (en) * 2019-08-28 2022-09-29 Lubrizol Advanced Materials, Inc. Drug-polymer amorphous solid dispersions using linear poly(acrylic acid) polymers
KR102266145B1 (ko) * 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체
WO2023025672A1 (fr) 2021-08-25 2023-03-02 Basf Se Composition auxiliaire de compression directe

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
DE2966564D1 (en) 1978-11-20 1984-02-23 American Home Prod Therapeutic compositions with enhanced bioavailability and process for their preparation
JPS5879915A (ja) * 1981-11-09 1983-05-13 Nippon Soda Co Ltd 棒状薬剤の製造方法
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
JPH0667840B2 (ja) * 1988-11-30 1994-08-31 萬有製薬株式会社 Ｎｂ―８１８の易吸収性製剤
US5028433A (en) 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
PT631578E (pt) * 1992-03-18 2001-11-30 Janssen Pharmaceutica Nv Estereoisomeros de itraconazol e saperconazol
DE4226753A1 (de) 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
JP3413238B2 (ja) 1993-03-31 2003-06-03 オリンパス光学工業株式会社 位相制御膜構造体
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
JP2948111B2 (ja) 1994-09-16 1999-09-13 塩野義製薬株式会社 経口投与用油性組成物

Also Published As

Publication number Publication date
HUP9901620A2 (hu) 1999-10-28
EE9800304A (et) 1999-02-15
US20060263436A1 (en) 2006-11-23
BR9706897B1 (pt) 2010-09-21
WO1997044014A1 (fr) 1997-11-27
DK0904060T3 (da) 2004-04-13
JPH11509238A (ja) 1999-08-17
PL330931A1 (en) 1999-06-07
HRP970270B1 (en) 2005-02-28
EA199800571A1 (ru) 1998-12-24
IL124935A0 (en) 1999-01-26
US6509038B2 (en) 2003-01-21
HRP970270A2 (en) 1998-04-30
NZ330739A (en) 1999-06-29
NO320495B1 (no) 2005-12-12
US8591948B2 (en) 2013-11-26
ES2212810T3 (es) 2004-08-01
US20140134244A1 (en) 2014-05-15
US9642806B2 (en) 2017-05-09
MX9805418A (es) 1998-10-31
US20030082239A1 (en) 2003-05-01
SK84898A3 (en) 1999-03-12
TW460282B (en) 2001-10-21
MY123827A (en) 2006-06-30
BG102532A (en) 1999-02-26
HU227745B1 (en) 2012-02-28
BG64368B1 (bg) 2004-12-30
IL124935A (en) 2001-06-14
AU722101B2 (en) 2000-07-20
AU2956297A (en) 1997-12-09
US20010007678A1 (en) 2001-07-12
US7081255B2 (en) 2006-07-25
PL188566B1 (pl) 2005-02-28
PT904060E (pt) 2004-04-30
ID16926A (id) 1997-11-20
SK284145B6 (sk) 2004-10-05
CA2240161A1 (fr) 1997-11-27
CA2240161C (fr) 2005-05-24
TR199801225T2 (xx) 1998-11-23
CN1165291C (zh) 2004-09-08
EP0904060A1 (fr) 1999-03-31
CZ188598A3 (cs) 1998-11-11
KR19990044257A (ko) 1999-06-25
EP0904060B1 (fr) 2003-12-10
EA001219B1 (ru) 2000-12-25
CZ293841B6 (cs) 2004-08-18
ATE255883T1 (de) 2003-12-15
CY2434B1 (en) 2004-11-12
HK1018002A1 (en) 1999-12-10
CN1209740A (zh) 1999-03-03
BR9706897A (pt) 1999-08-31
SI0904060T1 (en) 2004-04-30
NO982599L (no) 1998-11-19
HUP9901620A3 (en) 2000-03-28
DE69726729T2 (de) 2004-12-02
EE03902B1 (et) 2002-12-16
JP3391801B2 (ja) 2003-03-31
NO982599D0 (no) 1998-06-05
DE69726729D1 (de) 2004-01-22

Similar Documents

Publication Publication Date Title
AR007195A1 (es) Forma farmaceutica de dosificacion, proceso para prepararla y uso de la misma para la preparacion de un medicamento para el tratamiento de infecciones virales
Uskoković et al. In vitro analysis of nanoparticulate hydroxyapatite/chitosan composites as potential drug delivery platforms for the sustained release of antibiotics in the treatment of osteomyelitis
IT1282352B1 (it) Composizione farmaceutica, in particolare essiccata mediante congelamento, per somministrazione orale di ondansetron e metodo per
Shi et al. Regulating the balance of Th17/Treg cells in gut-lung axis contributed to the therapeutic effect of Houttuynia cordata polysaccharides on H1N1-induced acute lung injury
NO20062398L (no) Daglig, oral, kontrollert frigivnings oksycodon-doserings form
AR020015A1 (es) Composiciones de celecoxib
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
CY1110495T1 (el) Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
CA2293470A1 (fr) Derives de benzimidazole
JP2016512248A5 (fr)
JP2009536147A5 (fr)
WO2017141104A3 (fr) Procédé d'induction d'une réponse immunitaire prolongée
AR037239A1 (es) Composicion de valdecoxib de desintegracion intraoral, proceso para su preparacion, tableta que se obtiene y el uso de dicha composicion en la preparacion de un medicamento.
MY152540A (en) Powder formulation for valganciclovir
DE602004009552D1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
MA50189A (fr) Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
JP2017526697A5 (fr)
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
JP2016512247A5 (fr)
AR008886A1 (es) Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea
AU2024202195A1 (en) Chemokine CXCR4 receptor modulators and uses related thereto
WO2019203771A3 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la sitagliptine
PT1492773E (pt) Compostos de 4-(heterociclilo)-benzenossulfoximinapara o tratamento da inflamação
AU2003218130A1 (en) N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors

Legal Events

Date Code Title Description
FC Refusal